Akanda Corp. (AKAN)
USD 1.29
(2.38%)
USD 1.29
(2.38%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -27.73 Million USD | 65.71% |
| 2022 | -4.52 Million USD | -152.57% |
| 2021 | -2.15 Million USD | -361.98% |
| 2020 | -1.4 Million USD | -100.36% |
| 2019 | -702.01 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -2.03 Million USD | 0.0% |
| 2023 Q2 | -3.77 Million USD | -100.05% |
| 2023 Q3 | -976.03 Thousand USD | 74.17% |
| 2023 FY | - USD | 65.71% |
| 2023 Q1 | -1.88 Million USD | 77.39% |
| 2023 Q4 | -976.03 Thousand USD | 0.0% |
| 2022 Q1 | -4.57 Million USD | -78.85% |
| 2022 FY | - USD | -152.57% |
| 2022 Q3 | -3.75 Million USD | 60.18% |
| 2022 Q4 | -8.35 Million USD | -122.26% |
| 2022 Q2 | -9.44 Million USD | -106.13% |
| 2021 Q3 | -3.79 Million USD | -35790.27% |
| 2021 FY | - USD | -361.98% |
| 2021 Q4 | -2.56 Million USD | 32.47% |
| 2021 Q2 | -10.56 Thousand USD | 0.01% |
| 2021 Q1 | -10.56 Thousand USD | 97.98% |
| 2020 Q4 | -522.45 Thousand USD | 0.0% |
| 2020 FY | - USD | -100.36% |
| 2019 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Esperion Therapeutics, Inc. | -150.1 Million USD | 81.523% |
| Theratechnologies Inc. | -10.31 Million USD | -168.944% |
| Safety Shot Inc | -12.18 Million USD | -127.618% |
| Cosmos Health Inc. | -17.06 Million USD | -62.56% |
| Cronos Group Inc. | -72.14 Million USD | 61.558% |
| Ironwood Pharmaceuticals, Inc. | -924.86 Million USD | 97.001% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | 23.132% |
| Organogenesis Holdings Inc. | 36.03 Million USD | 176.977% |
| Universe Pharmaceuticals INC | -3.21 Million USD | -762.678% |
| ProPhase Labs, Inc. | -14.82 Million USD | -87.062% |
| Sonoma Pharmaceuticals, Inc. | -4.52 Million USD | -512.943% |
| Dynavax Technologies Corporation | 9.66 Million USD | 386.941% |
| Radius Health, Inc. | 38.31 Million USD | 172.398% |
| China SXT Pharmaceuticals, Inc. | -2.35 Million USD | -1079.735% |
| Alvotech | -484.86 Million USD | 94.28% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | -625.226% |
| Alpha Teknova, Inc. | -25.53 Million USD | -8.601% |
| Intra-Cellular Therapies, Inc. | -158.85 Million USD | 82.54% |
| SCYNEXIS, Inc. | 73.47 Million USD | 137.746% |
| Harrow Health, Inc. | 9.72 Million USD | 385.259% |
| Biofrontera Inc. | -18.45 Million USD | -50.304% |
| DURECT Corporation | -24.68 Million USD | -12.363% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 128.226% |
| ANI Pharmaceuticals, Inc. | 109.32 Million USD | 125.371% |
| OptiNose, Inc. | -15.55 Million USD | -78.33% |
| RedHill Biopharma Ltd. | 26.26 Million USD | 205.595% |
| Aquestive Therapeutics, Inc. | 1.18 Million USD | 2446.505% |
| Cumberland Pharmaceuticals Inc. | -710.85 Thousand USD | -3801.764% |
| SIGA Technologies, Inc. | 84.15 Million USD | 132.956% |
| Lifecore Biomedical, Inc. | 812 Thousand USD | 3515.725% |
| Shineco, Inc. | -26.55 Million USD | -4.45% |
| Phibro Animal Health Corporation | 84.6 Million USD | 132.782% |
| Procaps Group S.A. | 104.02 Million USD | 126.662% |
| TherapeuticsMD, Inc. | -8.4 Million USD | -230.147% |
| Regencell Bioscience Holdings Limited | -3.61 Million USD | -666.682% |
| Viatris Inc. | 3.51 Billion USD | 100.789% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | -625.226% |
| Rockwell Medical, Inc. | -4.69 Million USD | -490.875% |
| Incannex Healthcare Limited | -18.5 Million USD | -49.89% |
| Aytu BioPharma, Inc. | -1.01 Million USD | -2640.68% |
| Tilray Brands, Inc. | -72.84 Million USD | 61.924% |
| Collegium Pharmaceutical, Inc. | 308.32 Million USD | 108.996% |
| PetIQ, Inc. | 81.48 Million USD | 134.037% |
| Silver Spike Investment Corp. | 7.34 Million USD | 477.865% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 106.666% |
| Journey Medical Corporation | 1.92 Million USD | 1543.815% |
| Alimera Sciences, Inc. | 7.27 Million USD | 481.194% |
| Petros Pharmaceuticals, Inc. | -4.21 Million USD | -558.512% |
| Assertio Holdings, Inc. | -222.44 Million USD | 87.532% |
| Shuttle Pharmaceuticals Holdings, Inc. | -3.99 Million USD | -595.017% |
| Embecta Corp. | 245.4 Million USD | 111.302% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | -38.465% |
| Procaps Group, S.A. | 104.02 Million USD | 126.662% |
| PainReform Ltd. | -9.56 Million USD | -189.849% |
| Avadel Pharmaceuticals plc | -149.12 Million USD | 81.401% |
| Hempacco Co., Inc. | -12.77 Million USD | -117.139% |
| Talphera, Inc. | -9.84 Million USD | -181.809% |
| Pacira BioSciences, Inc. | 162.89 Million USD | 117.027% |
| Alvotech | -484.86 Million USD | 94.28% |
| Lantheus Holdings, Inc. | 491 Million USD | 105.649% |
| Kamada Ltd. | 21.53 Million USD | 228.8% |
| Indivior PLC | 66 Million USD | 142.024% |
| Currenc Group, Inc. | -1.9 Million USD | -1359.332% |
| Evoke Pharma, Inc. | -7.29 Million USD | -280.342% |
| Flora Growth Corp. | -45.87 Million USD | 39.534% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | -38.465% |
| Evolus, Inc. | -41.81 Million USD | 33.663% |
| HUTCHMED (China) Limited | 25.52 Million USD | 208.648% |
| Amphastar Pharmaceuticals, Inc. | 241.46 Million USD | 111.486% |